vs
Side-by-side financial comparison of CrowdStrike (CRWD) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.3B, roughly 1.1× CrowdStrike). Organon & Co. runs the higher net margin — 10.0% vs 3.1%, a 6.9% gap on every dollar of revenue. On growth, CrowdStrike posted the faster year-over-year revenue change (23.3% vs -3.5%). Over the past eight quarters, CrowdStrike's revenue compounded faster (19.0% CAGR vs -4.7%).
CrowdStrike Holdings, Inc. is an American cybersecurity technology company based in Austin, Texas. It provides endpoint security, threat intelligence, and cyberattack response services.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
CRWD vs OGN — Head-to-Head
Income Statement — Q1 FY2027 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.5B |
| Net Profit | $40.8M | $146.0M |
| Gross Margin | 75.8% | 53.6% |
| Operating Margin | 23.7% | — |
| Net Margin | 3.1% | 10.0% |
| Revenue YoY | 23.3% | -3.5% |
| Net Profit YoY | 424.5% | 67.8% |
| EPS (diluted) | $0.15 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $1.5B | ||
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.2B | $1.6B | ||
| Q2 25 | $1.1B | $1.6B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.0B | $1.6B | ||
| Q3 24 | $963.9M | $1.6B | ||
| Q2 24 | $921.0M | $1.6B |
| Q1 26 | $40.8M | $146.0M | ||
| Q4 25 | $-34.0M | $-205.0M | ||
| Q3 25 | $-77.7M | $160.0M | ||
| Q2 25 | $-110.2M | $145.0M | ||
| Q1 25 | $-92.3M | $87.0M | ||
| Q4 24 | $-16.8M | $109.0M | ||
| Q3 24 | $47.0M | $359.0M | ||
| Q2 24 | $42.8M | $195.0M |
| Q1 26 | 75.8% | 53.6% | ||
| Q4 25 | 75.1% | 49.2% | ||
| Q3 25 | 73.5% | 53.5% | ||
| Q2 25 | 73.8% | 54.8% | ||
| Q1 25 | 74.1% | 55.6% | ||
| Q4 24 | 74.7% | 56.3% | ||
| Q3 24 | 75.4% | 58.3% | ||
| Q2 24 | 75.6% | 58.4% |
| Q1 26 | 23.7% | — | ||
| Q4 25 | -5.6% | -9.8% | ||
| Q3 25 | -9.7% | 15.2% | ||
| Q2 25 | -11.3% | 14.4% | ||
| Q1 25 | -8.1% | 6.7% | ||
| Q4 24 | -5.5% | 8.1% | ||
| Q3 24 | 1.4% | 13.1% | ||
| Q2 24 | 0.8% | 14.6% |
| Q1 26 | 3.1% | 10.0% | ||
| Q4 25 | -2.8% | -13.6% | ||
| Q3 25 | -6.6% | 10.0% | ||
| Q2 25 | -10.0% | 9.1% | ||
| Q1 25 | -8.7% | 5.8% | ||
| Q4 24 | -1.7% | 6.8% | ||
| Q3 24 | 4.9% | 22.7% | ||
| Q2 24 | 4.6% | 12.1% |
| Q1 26 | $0.15 | $0.55 | ||
| Q4 25 | $-0.14 | $-0.78 | ||
| Q3 25 | $-0.31 | $0.61 | ||
| Q2 25 | $-0.44 | $0.56 | ||
| Q1 25 | $-0.37 | $0.33 | ||
| Q4 24 | $-0.07 | $0.42 | ||
| Q3 24 | $0.19 | $1.38 | ||
| Q2 24 | $0.17 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.2B | — |
| Total DebtLower is stronger | $745.5M | — |
| Stockholders' EquityBook value | $4.5B | — |
| Total Assets | $11.1B | — |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $5.2B | — | ||
| Q4 25 | $4.8B | $574.0M | ||
| Q3 25 | $5.0B | $672.0M | ||
| Q2 25 | $4.6B | $599.0M | ||
| Q1 25 | $4.3B | $547.0M | ||
| Q4 24 | $4.3B | $675.0M | ||
| Q3 24 | $4.0B | $763.0M | ||
| Q2 24 | $3.7B | $704.0M |
| Q1 26 | $745.5M | — | ||
| Q4 25 | — | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B |
| Q1 26 | $4.5B | — | ||
| Q4 25 | $4.0B | $752.0M | ||
| Q3 25 | $3.8B | $906.0M | ||
| Q2 25 | $3.5B | $733.0M | ||
| Q1 25 | $3.3B | $542.0M | ||
| Q4 24 | $3.1B | $472.0M | ||
| Q3 24 | $2.9B | $493.0M | ||
| Q2 24 | $2.5B | $144.0M |
| Q1 26 | $11.1B | — | ||
| Q4 25 | $10.0B | $12.9B | ||
| Q3 25 | $9.3B | $13.6B | ||
| Q2 25 | $8.7B | $13.5B | ||
| Q1 25 | $8.7B | $13.2B | ||
| Q4 24 | $7.8B | $13.1B | ||
| Q3 24 | $7.2B | $12.8B | ||
| Q2 24 | $6.8B | $12.2B |
| Q1 26 | 0.17× | — | ||
| Q4 25 | — | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | — | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.6B | — |
| Free Cash FlowOCF − Capex | $376.4M | — |
| FCF MarginFCF / Revenue | 28.8% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 39.54× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.6B | — | ||
| Q4 25 | $397.5M | $141.0M | ||
| Q3 25 | $332.8M | $264.0M | ||
| Q2 25 | $384.1M | $220.0M | ||
| Q1 25 | $345.7M | $75.0M | ||
| Q4 24 | $326.1M | $390.0M | ||
| Q3 24 | $326.6M | $141.0M | ||
| Q2 24 | $383.2M | $332.0M |
| Q1 26 | $376.4M | — | ||
| Q4 25 | $314.1M | $96.0M | ||
| Q3 25 | $302.3M | $218.0M | ||
| Q2 25 | $298.4M | $181.0M | ||
| Q1 25 | $258.5M | $43.0M | ||
| Q4 24 | $247.4M | $335.0M | ||
| Q3 24 | $287.4M | $99.0M | ||
| Q2 24 | $333.5M | $300.0M |
| Q1 26 | 28.8% | — | ||
| Q4 25 | 25.5% | 6.4% | ||
| Q3 25 | 25.9% | 13.6% | ||
| Q2 25 | 27.0% | 11.4% | ||
| Q1 25 | 24.4% | 2.8% | ||
| Q4 24 | 24.5% | 21.0% | ||
| Q3 24 | 29.8% | 6.3% | ||
| Q2 24 | 36.2% | 18.7% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 3.0% | ||
| Q3 25 | 2.6% | 2.9% | ||
| Q2 25 | 7.8% | 2.4% | ||
| Q1 25 | 8.2% | 2.1% | ||
| Q4 24 | 7.8% | 3.5% | ||
| Q3 24 | 4.1% | 2.7% | ||
| Q2 24 | 5.4% | 2.0% |
| Q1 26 | 39.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | — | 1.52× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | 6.95× | 0.39× | ||
| Q2 24 | 8.95× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRWD
| Subscription | $1.2B | 95% |
| Other | $63.1M | 5% |
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
